Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Re-treatment in mCRC
NCT01832467Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Apr 2013
- Primary completion
- Apr 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by The Chinese University of Hong Kong. Started Apr 2013; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01832467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01832467.